You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0159 Results of A Phase 1b Study of The Safety, Tolerability, and Pharmacokinetics of The MMP9 Inhibitor GS-5745 in Patients with Rheumatoid Arthritis (RA)

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016200
Aug 2016502
Sep 2016604
Oct 20162102
Nov 20161900
Dec 2016800
Jan 20171600
Feb 2017400
Mar 20171102
Apr 20172201
May 20172106
Jun 2017400
Jul 20171402
Aug 20171600
Sep 20172801
Oct 20173001
Nov 20172001
Dec 20173202
Jan 20184403
Feb 2018800
Mar 20183200
Apr 20181400
May 20184001
Jun 20181600
Jul 20181200
Aug 20181000
Sep 2018400
Oct 2018600
Nov 20181000
Dec 2018200
Jan 2019200
Feb 2019200
Apr 20191000
May 2019400
Jun 2019200
Jul 2019400
Oct 2019200
Nov 2019200
Dec 2019800
Jan 2020800
Feb 2020200
Apr 2020600
May 2020200
Jun 2020800
Jul 2020600
Aug 20201000
Sep 20201600
Oct 2020201
Nov 2020400
Dec 2020600
Jan 2021200
Oct 20211400
Nov 20211000
Dec 2021400
Jan 2022600
Feb 2022600
Mar 2022200
Apr 20221000
May 2022801
Jun 2022600
Jul 2022400
Aug 2022600
Sep 20221601
Oct 2022400
Nov 2022600
Dec 20221000
Jan 2023400
Feb 20231000
Mar 20231000
May 2023400
Jun 20231000
Jul 2023400
Aug 2023400
Sep 2023800
Oct 2023200
Dec 2023800
Jan 2024200
Feb 20241000
Mar 2024200
Total775031